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(NSCLC). Using data from the SEER-Medicare cancer registry,
we examined trends in use, outcomes, and costs of care for
NSCLC patients receiving chemotherapy in community settings
from 1994–2001. METHODS: Patients were included if they
were diagnosed with locally advanced or metastatic (TNM stages
IIIb and IV) NSCLC between 1 January 1994 and 31 December
2001. Patients were stratiﬁed based on initial chemotherapy
agent(s) used. Cox proportional hazards models were used to
compare survival as a function of initial chemotherapy regimen,
controlling for age, sex, race, noncancer comorbidity, stage at
diagnosis, SEER region, and receipt of cancer-related surgery or
radiation therapy in the ﬁrst 3 months following diagnosis. Life-
time medical costs were calculated for each chemotherapy group
using the Kaplan Meier sample average estimator. RESULTS: A
total of 14,875 met inclusion criteria, 7411 (49.8%) stage IIIb
and 7464 (50.2%) stage VI at diagnosis. Chemotherapy use in
the ﬁrst 3 months following diagnosis increased from 21% to
43% of those diagnosed over the observation period (p < 0.01).
Persons > = 75 (OR = 0.91), females (OR = 0.87), African Amer-
icans (OR = 0.49) and those with >1 comorbidity (OR = 0.84)
were signiﬁcantly less likely to receive chemotherapy. Multivari-
ate Cox proportional hazards models demonstrated that survival
was inferior for those not receiving a platinum agent (p < 0.01).
Lifetime medical care costs differed signiﬁcantly among regimens
[mean (std. dev.)]: no chemotherapy $27,833 (372); cisplatin or
carboplatin alone $128,179 (11,968); cisplatin or carboplatin
plus taxane $78,451 (2,898); cisplatin/carboplatin + other agent
not taxane $68,173 (2663) single agent or doublet excluding 
cisplatin or carboplatin $55,959 (2331). CONCLUSIONS:
Chemotherapy use for advanced NSCLC has increased substan-
tially. Platinum containing regimens (recommended by guide-
lines) are superior. Some combinations are more costly but do
not offer improved survival.
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OBJECTIVES: Targeted therapies, functional imaging and trans-
lational research have enabled utilization of a new endpoint in
phase I oncology trials, known as Surrogate Endpoints (SEs) or
biomarkers. Investigators hope that SEs will improve the efﬁ-
ciency of drug-development. However, whether SEs can substi-
tute for traditional endpoints is unknown. The role of SEs in
drug selection, target validation, dosing and schedule is not
deﬁned. METHODS: We analyzed phase I single-agent abstracts
in PASCO from 1992 to 2002 that included at least one SE. Sub-
sequent publications were analyzed based on the primary SE.
Drugs were classiﬁed as cytotoxic, biologic, or targeted and SEs
classiﬁed by their technology (imaging, blood biomarkers or
advanced histology). We designed 4 questions to evaluate the
role of SEs, beginning with: “Did the SE help . . . : 1) “. . . deter-
mine the dose for phase II?”; 2) “. . . in ﬁnding the schedule?”;
3) “. . . with the author’s conclusions?”; and 4) “. . . validate that
the target was affected?”. McNemar’s and chi-square tests com-
pared the utility of SEs across these questions and across drug
classes, respectively. We also related the budgets of 18 institu-
tional trials to their number of SEs. RESULTS: Of 74 trials, 57%
tested biologics, 24% small molecules, 14% cytotoxic and 5%
other. According to technology: 68% were blood studies, 24%
histologic analysis, and 7% imaging. The frequency of “yes” for
the 4 questions was 15%, 16%, 38%, and 62%, respectively (p
< 0.001 between questions), without differences between classes.
The budgeted cost of adding a SE was US$6675 per patient.
CONCLUSIONS: SEs modestly aided in deﬁning dose and
schedule for future studies and in the overall drug-development
process. They helped in validating that the therapy affected the
intended target. Better preclinical evaluation of SEs may enhance
their utility. Further research should help deﬁne how best to
incorporate SEs into trial design.
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OBJECTIVES: Prostate Cancer patients using Androgen Depri-
vation Therapy (ADT) are considered at a higher risk for osteo-
porotic fractures due to excessive loss of bone mineral density
(BMD). This study measured the incremental Cost Effectiveness
(CE) of adding bisphosphonates to ADT based on QALYs
gained. METHODS: A Markov model of fracture-risk associated
with osteoporosis in patients with non-metastatic prostate cancer
was developed to compare the incremental CE of adding
pamidronate or zoledronic acid to ADT. Literature-based esti-
mates of costs of treating osteoporotic fractures and average
wholesale prices of bisphosphonates were used. Disutilities pub-
lished by the National Osteoporotic Foundation for the ﬁrst and
subsequent year following an osteoporotic fracture were used to
measure effectiveness of prescribing bisphosphonates. Robust-
ness of assumptions was tested using deterministic and stochas-
tic sensitivity analyses. RESULTS: The Markov analyses yielded
total incremental cost of $17,009.40 for ADT + pamidronate
and of $25,838.90 for ADT + zoledronic acid over ADT only
option. Adding pamidronate resulted in a gain of 0.0128 QALYs
at a marginal CE of $1,327,746 as compared to zoledronic acid
which resulted in a gain of 0.015 QALYs at a marginal CE of
$1,722,593. Monte Carlo simulation as well as one-way and
two-way sensitivity analyses indicated robustness of the key
assumptions such as probability of fracture, probability of death
due to hip fracture and discount rate. CONCLUSIONS: In case
of reducing the fracture-risk in non-metastatic prostate cancer
patients using bisphosphonates resulted in nominal gain in
QALYs at a very high marginal CEs for both drugs.
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OBJECTIVES: Basal cell carcinoma (BCC) is a common malig-
nant tumour, usually treated with surgery though the cosmetic
appearance of the treated lesions can be poor. Methyl aminole-
vulinate cream is the ﬁrst topical PDT therapy licensed in the UK
for superﬁcial, or mid-face, large or recurrent nodular BCC and
can be considered for lesions unsuitable for surgery. The aim of
this evaluation was to assess the cost-effectiveness of MAL-PDT
versus excision. METHODS: Clinical outcomes were from a
comparative trial of nodular BCC. The clinical response for
MAL-PDT from a non-comparative trial of primary superﬁcial
BCC (Horn et al, in press) was also used to reﬂect the subgroup
most likely to be treated with MAL-PDT. Lesion reoccurrence
was derived from published literature and an expert Delphi panel
provided resource use. The NHS perspective was taken and only
direct costs were considered. Decision analysis was used with
MAL-PDT or excision as ﬁrst line therapy and, if no lesion
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response, second line therapy. A one-year time horizon was used
to capture all relevant outcomes. Excellent cosmetic outcome
was deﬁned as 100% complete lesion response, with no scarring,
atrophy or induration, and no or slight occurrence of redness or
change in pigmentation compared to adjacent skin. Clinical data
from the trials were subjected to stochastic sensitivity analysis.
RESULTS: From the deterministic model, 69% of nodular BCC
patients had an excellent cosmetic outcome with MAL-PDT at
a cost of £988.47 per patient compared to 36% of patients
treated by excision (£772.91 per patient). Substituting the super-
ﬁcial BCC efﬁcacy data, the cost of MAL-PDT was found to be
£890.35 with a 75% excellent cosmetic outcome. In the sto-
chastic analysis using 1000 simulations, 95% of the ICERs 
calculated were in the range £17 to £2816. CONCLUSIONS:
MAL-PDT is advantageous for cosmetically sensitive areas such
as lesions on the face and has comparable costs.
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OBJECTIVES: Although higher density chemotherapy regimens
could improve treatment outcomes, febrile neutropenia and its
related complications often limit the density of chemotherapy
administration to a suboptimal level. Filgrastim-enabled
chemotherapy regimens administered at a high density were
shown to increase survival among breast cancer patients in a
recent clinical trial (Citron et al, 2003). The high costs of ﬁl-
grastim and time loss of patients and caregivers due to frequent
administration, motivated an economic analysis to compare the
cost-effectiveness of dose-dense therapy with ﬁlgrastim vs. con-
ventional chemotherapy in breast cancer patients. METHODS:
Target Population: Women with node-positive breast cancer.
Time Horizon: Twelve cycles of chemotherapy with lifetime
follow up. Perspective: Societal. Data Sources: The Intergroup
Trial C9741 was the primary source of treatment efﬁcacy, rates
of febrile neutropenia with and without hospitalization, and
other major toxicities. Direct health care cost components and
indirect costs of patient and caregiver time loss were obtained
from literature review. Measurements: Discounted lifetime costs
were estimated based on a decision model. Discounted quality-
adjusted life years (QALYs) was estimated based on the DEALE
method. Incremental cost-effectiveness ratios (ICERs) were cal-
culated for each age group at 5-year interval. RESULTS: Under
the base case assumptions, dose-dense chemotherapy incurred
cost $25,530 higher than conventional therapy over lifetime, and
the average discounted survival beneﬁts were 1.400 QALYs per
patient. This resulted in an average cost-effectiveness ratio of
$19,940 per QALY saved. ICERs were $13,672/QALY in age
group 30–34, and this ratio increased with age to $34,418/
QALY in age group 75–80, indicating a more favorable cost-
effectiveness in younger women. Results of the model were rel-
atively stable when the parameters changed within a reasonable
range. CONCLUSIONS: From a societal prospective, dose-dense
chemotherapy with ﬁlgrastim in breast cancer patients is a cost-
effective improvement compared to conventional chemotherapy.
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OBJECTIVES: This study estimated the costs of treating pan-
creatic cancer and evaluated the additional costs when initial
treatment failed and secondary treatment or terminal care were
needed. METHODS: This claims-based retrospective study used
the MarketScan Commercial and Medicare databases. The study
included patients ﬁrst diagnosed with pancreatic cancer (ICD-9-
CM 157.xx) between January 1, 1999 and November 30, 2000.
A demographically-matched control group was selected at a ratio
of 3 :1. Non-terminal treatment provided to cancer patients upon
diagnosis was categorized as initial treatment. Chemotherapy
switches or additional treatment occurring three months after 
the end of initial treatment were noted as secondary treatment
following treatment failure. Care provided after the onset of
advanced disease, during the 12 months prior to death, or in hos-
pices or nursing facilities was deﬁned as terminal treatment.
Monthly mean costs were adjusted for age, gender, Charlson
Comorbidity Index, region, follow-up length and hospital mor-
tality using ordinary least square regression. RESULTS: The
study included 412 cancer patients and 1236 matched controls.
Mean follow-up was 7.5 months. Adjusted mean monthly health
care costs were $7613 for cancer patients and $334 for controls
(p < 0.05). Inpatient care accounted for the majority of costs
among cancer patients. Approximately half (51.7%) of the eli-
gible patients did not respond to initial treatment, and these
patients incurred $15,000 more per month than patients who
required no additional treatment. The costs of additional treat-
ment and higher initial treatment costs contributed to the cost
burden of treatment failure. CONCLUSIONS: The direct costs
of pancreatic cancer are substantial, and these costs are especially
pronounced when initial treatment fails. The causes of treatment
failure, and the interventions that may prevent or delay these
occurrences, should be investigated further.
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OBJECTIVE: Clinical trial data has proven hormonal therapy
increases survival time when added to a radiation treatment
strategy for locally advanced prostate cancer. The purpose of this
analysis was to assess from the payers’ perspective the cost effec-
tiveness of adding hormonal therapy to radiation therapy when
treating patients with locally advanced prostate cancer.
METHODS: A decision tree model incorporating a Markov
process was developed using DATA 4.0 to determine the cost
associated with a locally advanced prostate cancer patient
gaining an additional year of life as a result of adding goserelin,
a gonadotropin-releasing hormone agonist analogue, to a radia-
tion treatment strategy. Data on the effectiveness of each strat-
egy was obtained from published clinical trials. Costs were based
on the literature and data from the US Centers for Medicaid and
Medicare Services and the UK Department of Health. All costs
and beneﬁts were discounted at ﬁve percent. Conventional and
probabilistic sensitivity analyses were used to assess model
robustness. RESULTS: Over a 9-year period, expected costs of
treatment with radiation alone and with radiation plus gosere-
lin are $7582 and $25,299, respectively, leading to an incre-
mental cost of $17,718 to add hormonal therapy to a radiation
only treatment strategy. In terms of effectiveness, over a nine-
year period, patients treated with hormonal therapy in addition
to radiation therapy gain an average of 0.65 years of life. The
incremental cost effectiveness of combination therapy over radi-
ation alone is $30,887 per additional life-year gained. Varying
